A histopathologic screening method for rational use of organs from prostate-specific antigen-positive multiorgan donors: The Italian Emilia-Romagna Region experience

Transplantation

Volumn 78, Issue 6, 2004, Pages 941-944

  D'Errico Grigioni, Antonia ^a   Corti, Barbara ^a   Fiorentino, Michelangelo ^a   Pirini, Maria Giulia ^a   Ridolfi, Lorenza ^b   Venturoli, Nicola ^b   Grigioni, Walter Franco ^a,b  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Organ donation; Pathology; Prostate cancer; Transplantation

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGE; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER RISK; CANCER SCREENING; CLINICAL ARTICLE; ECHOGRAPHY; ENZYME ASSAY; FROZEN SECTION; HISTOPATHOLOGY; HOSPITAL ADMISSION; HUMAN; HUMAN TISSUE; ITALY; MALE; ORGAN DONOR; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; RISK BENEFIT ANALYSIS; SAFETY; SCREENING TEST;

AGED; AGED, 80 AND OVER; HUMANS; ITALY; MALE; MIDDLE AGED; ORGAN SIZE; PATIENT SELECTION; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TISSUE DONORS;

EID: 4644318234     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000136989.87896.A4     Document Type: Article

References (11)

1. Garzotto M, Hudson RG, Peters L, et al. Predictive modeling for the presence of prostate carcinoma using clinical, laboratory, and U.S. parameters in patients with prostate specific antigen levels < or = 10 ng/mL. Cancer 2003; 98: 1417.
2. Khan MA, Partin AW, Rittenhouse HG, et al. Evaluation of prostate specific antigen for early detection of prostate cancer in men with a total prostate specific antigen range of 4.0 to 10.0 ng/ml. J Urol 2003; 170: 723.
3. Loh E, Couch FJ, Hendricksen C, et al. Development of donor-derived prostate cancer in a recipient following orthotopic heart transplantation. JAMA 1997; 227: 133.
4. Buell JF, Trofe J, Hanaway MJ, et al. Transmission of donor cancer into cardiothoracic transplant recipients. Surgery 2001; 130: 660.
5. Feng S, Buell JF, Cherikh WS, et al. Organs donors with positive viral serology or malignancy: risk of disease transmission by transplantation. Transplantation 2002; 74: 1657.
6. Kauffman HM, McBride MA, Cherikh WS, et al. Transplant tumor registry: donor related malignancies. Transplantation 2002; 74: 358.
7. Fiorentino M, D'Errico A, Corti B, et al. A multiorgan donor cancer screening protocol: The Italian Emilia-Romagna Region experience. Transplantation 2003; 76: 1695.
8. Association of Directors of Anatomic and Surgical Pathology. Recommendations for the reporting of resected prostate carcinomas. Hum Pathol 1996; 27: 321.
9. Bostwick DG, Grignon, DJ, Hammond EH, et al. prognostic factors in prostate cancer. College of American Pathologists consensus conference statement 1999. Arch Pathol Lab Med 2000; 124: 995.
10. Micheli A, Mugno E, Krogh V, et al. Cancer prevalence in European registry areas. Ann Oncol 2002; 13: 840.
11. Verdecchia A, Micheli A, Colonna M, et al. A comparative analysis of cancer prevalence in cancer registry areas of Florence, Italy and Spain. Ann Oncol 2002; 13: 1128.